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ABSTRACT
In the treatment of hydatid cysts, surgical Intervention 
is still the primary method. In cases with multiple organ 
involvement, medical treatment with the
benzimidazole group drugs (Mebendazole-
Albendazole) has been reported to reveal promising 
results. We reported this case because of multiple 
organ involvement including posterior fossa 
involvement which is t|uite rare. We also discussed 
treatment results and drug efficacy with the literature 
review. A 24 year old female presented to our 
department with complaing of headache, cough and a 
foul smelling fluid regurgitating from the mouth that 
was of 15 days duration. Multiple cysts of various sizes 
and location were revealed on the chest x-ray. Multiple 
cysts in the liver, spleen, and kidneys were seen on 
the abdominal ultrasonography, and a cystic formation 
in the posterior cranial fossa was observed on the 
cranial computerized tomography. The indirect 
hemagglutination test was positive at the titration of 
1:92400. Five courses of therapy each lasting four 
weeks with 800 mg/day Albendazole led to the 
dissolution of the cysts in the brain, kidneys and 
decrease in the number and / or size of the cysts in the 
spleen and liver. The contents of the cysts in the lungs 
were drained with the cyst wall being visible on x-ray.
Key W ords: Albendazole, Multiple organ 
involvement, Hydatid cyst
INTRODUCTION
Echinococcus granulosus is a cestode responsible for 
the hydatid cyst, a parasitic infestation. It is endemic in 
the regions of South America, Australia, North Africa,
Mediterranean and Middle Eastern countries. It is also 
endemic in Turkey and is a common parasitic disease 
with the incidence 1 :2 0 0 0  (1 ).
The hydatid cyst is generally asymptomatic clinically, 
but has a considerable rate of morbidity and in rare 
cases leads to mortality. The liver is commonly 
affected (60-70%), with lung (10-30%), muscle, 
kidney, spleen, bone, thyroid, and pancreas 
involvement following. There is brain involvement at a 
rate of 1-2% (2 ).
Definite diagnosis may be established by radiology, 
ultrasonography, computerized tomography, and 
serology. Echinococcal Indirect Hemagglutination 
Test, Casoni Skin Test, ELISA, or Complement 
Fixation Test are applicable serological investigation 
methods.
In the treatment, surgical intervention is still the 
primary choice. However benzimidazole group of 
pharmaceuticals may be preferred in medical therapy 
when there are multiple cysts. The response to therapy 
varies according to the localization and size of the 
cysts (3,4).
CASE REPORT
A 24-year-old female presented to our department with 
the complaints of headache, cough and a foul smelling 
fluid regurgitating from the mouth that was of 15 days 
duration. There were bilateral rales and rhonci on 
auscultation of the chest. There was hepatomegaly, 2 
cm below the costal margin on the mid-clavicular line 
on palpation of the abdomen. The laboratory 
investigation results were as follows: the white-blood 
cell count was 8700/mm3, hemoglobin level was 11.4
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g/dl, the hematocrit was 33%, mean corpuscular 
volume was 80.7 fl, platelet count was 363,000/mm3. 
The peripheral blood smear showed 54% 
polymorphonuclear leukocytosis, 28% lymphocytosis, 
8% monocytosis, and 10% eosinophilia. Erythrocyte 
sedimentation rate was 52 mm/hr. In the lung x-ray, 
there were variable sized, nodular opacities of uniform 
contour and contents in the lower and middle zones of 
both lungs (Fig. 1 a). In the abdominal ultrasonography, 
there was a solitary cyst in the right middle lobe of the 
liver at 8x10mm size (Fig. 1b), three cysts were in the 
spleen located subdiaphragmatically at sizes of 14, 19, 
and 13 mm (Fig. 1c), and a uniform cyst was in the 
middle pole of the right kidney at a size of 14 mm (Fig.
1 d), A cystic lesion of 2.5 cm diameter at the fourth 
ventricle of the cerebellum was revealed by cranial 
computerized tomography with contrast enhancement 
(Fig. 1 e). The indirect hemagglutination test was 
positive at the titration of 1:92400. As there was 
multiple organ involvement with multiple cysts and 
there was a deeply localized lesion in the posterior 
cranial fossa which had a high risk of perforation, 
medical treatment with albendazole was preferred. 
The patient used 800 mg albendazole per day for four 
weeks and this was repeated as five courses. Regular 
outpatient follow-up was instituted. After five courses 
of therapy, each lasting four weeks, the cranial cystic 
lesion shown by the cranial computerized tomography
Fig,1 a: X-ray showing variable sized nodular opacities in 
the lower and middle zones ot both lungs before 
therapy.
Fig.1c: Ultrasonography showing 14, 
19 and 13 mm hydatid cysts in 
the spleen.
RK
Fig.ld: Ultrasonography showing 14 mm 
hydatid cyst in the middle pole of 
right kidney (RK) before therapy.
Fig.1b: Ultrasonography showing hydatid cyst in the 
liver.
Fig.le: CT showing 2.5 cm hydatid cyst at the location of 
4 th ventricle before therapy.
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Fig.2a: X-ray showing cyst condition after one course of 
therapy.
Fig.2b: CT showing cyst size reduction after one course of 
therapy.
Fig.2c: CT showing loss of cranial cyst after 3 courses of 
therapy.
vanished, the lesions in the kidney disappeared and the 
lesions in the spleen and liver decreased in number and 
/ or size and there was no need to operate. The cystic 
lesions in the lungs were drained spontaneously and only 
the walls were visible on the chest x-ray (Fig. 2a). The 
first course of Albendazole treatment lasting four weeks 
showed a decrease in the number of the cystic lesions in 
the spleen and noticeable decrease in the size of the 
cranial lesion (Fig. 2b) and emptying of the lung lesions 
with only the walls being visible radiographically. The 
second course of four weeks duration led to the 
disappearance of the renal cysts. At the end of the third 
course the cranial cyst was lost (Fig. 2c) .The complaints 
of head-ache, vergio and cough resolved with the 
treatment. The echinococcal indirect hemagglutination 
titers were 1:92400 initially, 1:56000 at the end of the 
second course, became 1 :1 2 0 0 0  at the end of the foruth 
course and decreased to 1:1024 at the end of the fifth 
course. The patient is still following up.
DISCUSSION
In the treatment of the hydatid cyst, surgical intervention 
is still the primary choice (4). Nevertheless, surgical 
treatment has led to a mortality rate of 3% and recurrence 
rate of 30% (1). In the last years, instead of only surgical 
treatment, uni-drug or multi-drug pharmaceutical therapy 
protocols have been developed as medical treatment or 
in combination with surgery (1). The most common drugs 
used in medical treatment are the benzimidazole group 
(albendazole-mebendazole).
Albendazole is the most recent benzoimidazole 
compound for the treatment of human hydatid disease. It 
is an oral anti-helmintic drug with a wide spectrum. It 
prevents the glucose uptake of the larva and adult forms 
of the parasite to the glycogen stores and hinders the 
production of ATP. During the course of the treatment, 
hepatic function tests, leukocyte and platelet counts and 
proteinuria should be under careful follow-up. The side 
effects are reversible and may be listed as high values of 
transaminases, thrombocytopenia, neutropenia, 
alopecia, and rarely gastointestinal upset, headache, 
fever and rash (5-8).
Mebendazole is the first of the benzimidazole group. It 
has a decreased rate of use due to its low degree of 
penetration across the cyst wall therefore allowing live 
parasites within the cyst fluid (7). Albendazole is better 
absorbed than mebendazole and has a higher degree of 
ability to reach high concentrations in the tissue, cyst 
wall, cyst fluid, cerebrospinal fluid and serum (6 -8 ). There 
is no definite recommendation for the length of the 
medical treatment, but it is advised to prolong it for large 
lesions (6 ). In a multi-centered study done by the World 
Health Organization, it was concluded that for objective
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evaluation of the results of albendazole treatment, 
there was a need for a follow-up period of twelve 
months (9). There are variable reports in the literature 
over the results of therapy with the benzimidazole 
group drugs. Morris et. al. investigated on a series of 
32 patients, 13 of which had multiple organ 
involvement, 6 of which had a previous round of 
treatment with mebendazole, 11 of which had 
recurrent postoperative lesions and treated them with 
10 mg/kg/day of albendazole. They concluded that 
cystic lesions vanished in 5 patients, decreased in size 
in 10 patients wtih protoscolexes discovered during 
surgery in 2 patients (5). Teggi et. al. evaluated 337 
patients, 68  of which had multiple organ involvement. 
Mebendazole was administered to 121 patients while 
albendazole was given to 216 patients. Albendazole 
showed a success rate of 49.3 %, a failure rate of 
31.5% and a recurrence rate of 30.9%. On the other 
hand mebendazole showed a succes rate of 15.6% 
and a failure rate of 48.1% (8 ). Khuroo et. al. tried 
albendazole on 33 patients and only 2 (18.2%) showed 
cure (10). Singounas et.al. reported success with 
albendazole in a case of intracerebral hydatid cyst. 
Our case, showed recovery concluded by 
disappearance of the cranial and renal cystic lesions, 
decrease in the number of the splenic and hepatic 
lesions, ad dissolution of the cystic contents with only 
the wall remaining in the lesions of the lung.
The treatment results wtih albendazole are 
encouraging. Nevertheless, the variable results are not 
surprising, since the penetration ability depends on the 
thickness of the ectocyst and acceptable results are 
obtained within a month with lesions of thin walled 
peritoneal and pleural cysts (5). As a result in cases 
that are inoperable, or present with multicysts or multi­
organ involvement the use of benzimidazole group of 
drugs is probably the only choice.
Albendazole out of this group seems to be the best 
alternative present among possible drugs. We suggest 
that inoperable patients or patients with multiple organ 
involvement should be treated with albendazole and 
should be monitored for up to 12 months before they 
are considered cured.
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